AJG 555

Drug Profile

AJG 555

Alternative Names: AJG-555

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Norgine
  • Developer EA Pharma
  • Class Laxatives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Constipation

Most Recent Events

  • 23 Oct 2017 EA Pharma completes a phase III trial in Constipation (In adolescents, In adults) in Japan (PO), before October 2017 (JapicCTI163167)
  • 23 Oct 2017 EA Pharma completes a phase III trial in Constipation (In children, In adolescents) in Japan (PO), before October 2017 (JapicCTI163382)
  • 29 Sep 2017 EA Pharma and Mochida Pharmaceuticals agree to co-develop and commercialise AJG 555 for Constipation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top